I develop new statistical methods to learn the fraction who benefit from treatment, using randomized trial data. Defined in the potential outcomes framework, the fraction who benefit is the proportion of patients whose potential outcome under treatment is better than that under control. Since only one potential outcome can be observed for any given person, this fraction is a non-identifiable parameter unless strong assumptions are made about the joint probability distribution of the potential outcomes. A strength of my methods is that they do not require assumptions about the joint distribution, but can incorporate a wide range of user-defined assumptions based on subject matter knowledge. I derive sharp lower and upper bounds on the fracti...
We focus on estimating the average treatment effect in a randomized trial. If base-line variables ar...
Hospital-free days (HFD) is a composite outcome combining information on mortality and hospitalizati...
Cure rate estimation is one of the most important issues in clinical trials and cure rate models are...
The fraction who benefit from treatment is the proportion of patients whose potential outcome under ...
Numerous human medical problems or diseases have been aided by the development of effective treatmen...
The primary analysis in many randomized controlled trials focuses on the average treatment effect an...
Cardiovascular disease (CVD) is the most frequent cause of deaths worldwide [1]. Scien-tists have do...
This work focuses on two examples of randomized control trials- a set of Phase II and Phase III clin...
My thesis work focuses on developing reliable and innovative statistical methods for improving analy...
In randomized trials with time-to-event outcomes, the hazard ratio (HR) is the most commonly used me...
We present a general method for estimating the effect of a treatment on an ordinal outcome in random...
In this thesis, we investigate sample size calculation for three kinds of clinical trials: (1). Rand...
This paper is a practical guide to the essentials of statistical analysis and reporting of randomize...
Instrumental variables methods are frequently used to analyze data from randomized trials with nonad...
Generally the primary goal of randomized clinical trials (RCT) is to make comparisons among two or m...
We focus on estimating the average treatment effect in a randomized trial. If base-line variables ar...
Hospital-free days (HFD) is a composite outcome combining information on mortality and hospitalizati...
Cure rate estimation is one of the most important issues in clinical trials and cure rate models are...
The fraction who benefit from treatment is the proportion of patients whose potential outcome under ...
Numerous human medical problems or diseases have been aided by the development of effective treatmen...
The primary analysis in many randomized controlled trials focuses on the average treatment effect an...
Cardiovascular disease (CVD) is the most frequent cause of deaths worldwide [1]. Scien-tists have do...
This work focuses on two examples of randomized control trials- a set of Phase II and Phase III clin...
My thesis work focuses on developing reliable and innovative statistical methods for improving analy...
In randomized trials with time-to-event outcomes, the hazard ratio (HR) is the most commonly used me...
We present a general method for estimating the effect of a treatment on an ordinal outcome in random...
In this thesis, we investigate sample size calculation for three kinds of clinical trials: (1). Rand...
This paper is a practical guide to the essentials of statistical analysis and reporting of randomize...
Instrumental variables methods are frequently used to analyze data from randomized trials with nonad...
Generally the primary goal of randomized clinical trials (RCT) is to make comparisons among two or m...
We focus on estimating the average treatment effect in a randomized trial. If base-line variables ar...
Hospital-free days (HFD) is a composite outcome combining information on mortality and hospitalizati...
Cure rate estimation is one of the most important issues in clinical trials and cure rate models are...